Topic: Pfizer Inc.
Monday Pfizer (PFE) announced that Sutent failed to prolong survival of lung cancer patients when given in combination with Tarceva. The indication Arqule is pursuing is very similar to that pursued by Pfizer, so had the Sutent trial been successful, it would ...
Pfizer Inc. (NYSE:PFE) announced today that the SUN 1087 trial of sunitinib in combination with erlotinib versus erlotinib demonstrated a statistically significant improvement in Progression-Free but not in Overall Survival in patients with previously treated advanced non-small cell lung cancer (NSCLC). Over ...
A new experimental drug helps shrink tumors in lung cancer patients with a specific form of genetic alteration, according to results from a clinical trial unveiled Saturday.The Pfizer Inc. drug crizotinib shrank tumors in patients with advanced non-small cell lung cancer (NSCLC) ...
Pfizer drug shows big promise in early testing for lung cancer patients with a certain geneDoctors are reporting unusually high success rates from early tests of an experimental lung cancer drug.The drug, called crizotinib, (crih-ZAH-tin-ib), is made by Pfizer Inc. It targets ...
NEW YORK (Reuters) - An experimental drug being developed by Pfizer Inc that targets a specific gene mutation demonstrated impressive anti-tumor activity in patients with advanced non-small cell lung cancer (NSCLC), according to data from a small study presented on Saturday.More than ...
Pfizer Inc. said Thursday it discontinued a late-stage study of the drug candidate figitumumab in patients with late-stage lung cancer, citing a lack of effectiveness.. "This outcome is disappointing to us and to patients with non-small cell lung cancer," said Dr. Mace ...
Pfizer Inc. announced today the discontinuation of A4021018 (also known as ADVIGO 1018), a Phase 3 trial examining the effects of investigational compound figitumumab (CP-751,871) in combination with erlotinib as a second/third-line treatment in patients with previously treated advanced non-adenocarcinoma non-small cell ...
NEW YORK (Reuters) - Pfizer Inc said on Tuesday it has ended a late-stage lung cancer study of its experimental drug figitumumab after an analysis showed it was unlikely to meet the main goal of improving overall survival.The analysis by an independent ...
NEW YORK (Reuters) - Pfizer Inc has halted patient enrollment in a late-stage lung cancer trial of its experimental drug, figitumumab, for safety reasons, the drugmaker said on Friday.The halt was recommended by independent safety monitors overseeing the study. As of Sept ...
Pfizer Inc has halted patient enrollment in a late-stage lung cancer trial of its experimental drug, figitumumab, for safety reasons, the drugmaker said on Friday. Pfizer said currently enrolled patients may continue their treatment in consultation with their physicians. The enrollment halt ...
Photo Gallery
-
Pfizer Settlement
FBI Assistant Director of Criminal Investigative Division Kevin Perkins, right, looks on ...AP News - -
Pfizer CEO
Jeffrey Kindler, chairman and CEO of Pfizer, speaks at a news conference ...AP News - -
Pfizer to acquire Wyeth for $68 billion dollars
epa01614571 Jeffery B. Kindler, Chairman and CEO of Pfizer (L) speaks as ...ZUMA Press Inc -
From Around the Web
Video Gallery
-
Pfizer is Recalling Birth Control Pills
Pfizer Inc. is recalling about a million packages of two ...2012-02-01 -
Pfizer Recalls Some Birth Control Pills
Pfizer Inc. is recalling 28 lots of birth control pills ...2012-02-01 -
Company Profile: Pfizer Inc.
The company is the world's largest research-based pharmaceuticals firm ...2010-04-08
